

- Abbott Laboratories Ltd. Humira, summary of product characteristic. 2011.
- Abdulaev N. G. Popp M. P., Smith W. C. and Ridge K. D. 1997. Functional expression of bovine opsin in the methylotropic yeast *Pichia pastoris*. *Protein Expression and Purification* **10**:61-69.
- Aggarwal B. B. 1987. Tumor necrosis factors: TNF- α and TNF- β their structure and pleiotropic biological effects. *Drugs of the Future***12**:891-898.
- Aggarwal B. B. 2004. Nuclear factor-kappaB: the enemy within. *Cancer Cell***6**(3):203-208.
- Aggarwal B. B., Ajoy Samanta and Marc Feldmann 2001. Cytokine reference: a compendium of cytokines and other mediators of host defense. Vol. 2. San Diego, Calif., *Academic Press*.
- Aggarwal B. B., Eessalu T. E. and Hass P. E. 1985. Characterization of receptor for human tumor necrosis factor and their regulation by interferon. *Nature***318**:665-667.
- Aggarwal B. B., Khor W. J., Hass P. E., Moffat B., Spencer S. A., Henzel W. J., Bringman T. S., Nedwin G. E., Goeddel D. V. and Harkins, R. N. 1985b. Human tumor necrosis factors: production, purification and characterization. *J. Biol. Chem* **260**: 2345-2354.
- Aggarwal B. B., Subash C. Gupta and JiHye Ki 2012. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood***119**:3
- Ahmad M., Hirz M., Pichler H., Schwab H. 2014. Protein expression in *Pichia pastoris*: recent achievements and perspectives for heterologous protein production. *Appl Microbiol Biotechnol***98**(2):5301-5317.
- Alexopoulou L., Pasparakis M., Kollias G. 1997. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. *Eur. J. Immunol.* **27**(10):2588-2592.

- ArbabiGhahroudi M., Desmyter A., Wyns L., Hamers R. and Muyldermans S. 1997. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. *FEBS Lett.***414**:521–526.
- Ario de Marco 2011. Biotechnological applications of recombinant single-domain antibody fragments. *Microbial Cell factories***10**(44):1-14.
- Armitage R. J. 1994. Tumor necrosis factor receptor superfamily members and their ligands. *Curr. Opin. Immunol.***6**:407-413.
- Barbas C. F. and Burton D. R. 1996. Selection and evolution of high-affinity human antiviral antibodies. *Trends Biotechnol.***14**: 230–234.
- Barbas C. F., Bain J. D., Hoekstra D.M. and Lerner R. 1992. Semisynthetic combinatorial libraries: a chemical solution to the diversity problem. *Proc. Natl. Acad. Sci. USA* **89**:4457–4461.
- Barbas C. F., Collet T. A., Amberg W., Roben P., Binley J. M., Hoekstra D., et al. 1993. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. *J. Mol. Biol.***230**: 812–823.
- Barbas C.F., Kang A.S., Lerner R.A. and Benkovic S. J. 1991. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. *Proc. Natl. Acad. Sci. USA* **88**: 7978-7982.
- Barnard G. C., Kull A. R., Sharkey N. S., Shaikh S. S., Rittenhour A. M., Burninal, et al. 2010. High-throughput screening and selection of yeast cell lines expressing monoclonal antibodies. *J. Ind. Microbiol. Biotechnol.***37**: 961-971.
- Bartal A. H., Hirshaut Y. 1987. Methods for hybridoma formation. Vol. 7. *The Humana press Inc.*
- Becker D. M. and Guarente L. 1991. High-efficiency transformation of yeast by electroporation. *Methods Enzymol.***194**:182–187.

- Better M., Chan C. P., Robinson R. R. and Horwitz A. H. 1988. *Escherichia coli* secretion of an active chimeric antibody fragment. *Science***240**:1041–1043.
- Black R. A., Rauch C. T., Kozlosky C. J., Peschon J. J., Slack J. L., Wolfson M. F., Castner B. J., Stocking K. L., Reddy P., Srinivasan S., Nelson N., Boiani N., Schooley K. A., Gerhart M., Davis R., Fitzner J. N., Johnson R. S., Paxton R. J., March C. J., Cerretti D. P. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor- α from cells. *Nature* **385**(6618): 729–733
- Boder E. T. and Wittrup K. D. 1997. Yeast surface display for screening combinatorial polypeptide libraries. *Nat. Biotechnol.***15**: 553–557.
- Boder E. T., Midelfort K. S., Wittrup K. D. 2000. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. *Proc Natl Acad Sci U S A.* **97**(20):10701–5.
- Boulianne G.L., Hozumi N. and Shulman M. J. 1984. Production of functional chimaeric mouse/human antibody. *Nature* **312**: 643–646.
- Bradford M.M. 1976. A dye binding assay for protein. *Anal. Biochem.***72**:248–254.
- Brierley R. A. 1998. Secretion of recombinant human insulin-like growth factor I (IGF-1). *Methods Mol Bio***103**:149–177.
- Broukaert P., Libert C., Everaerd B., and Fiers W. 1992. Selective species specificity of tumor necrosis factor for toxicity in the mouse. *Lymphokine Cytokine Res.***11**:193–196.
- Brown C.T., Davis-Richardson A. G., Giongo A., Gano K. A., Crabb D. B., Mukherjee N., Casella G., Drew J. C., Ilonen J., Knip M., Hyöty H., Veijola R., Simell T., Simell O., Neu J., Wasserfall C. H., Schatz D., Atkinson M. A., Triplett E. W. 2011. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. *PLoS One***6**(10): e25792.

- Butler Mark S., Avril A. B. Robertson and Matthew A. Cooper 2014. Natural product and natural product derived drugs in clinical trials. *Nat. Prod. Rep.***31**:1612-1661.
- Cai X. H. and Garen A. 1995. Anti-melanoma antibodies from melanoma patients immunised with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. *Proc. Natl. Acad. Sci. USA* **92**:6537–6541.
- Cappellaro C., Baldermann C., Rachel R. and Tanner W. 1991. Saccharomyces cerevisiae a- and alpha-agglutinin: characterization of their molecular interaction. *EMBO J.* **13**:4737– 4744.
- Cereghino G. P., Cereghino J. L., Ilgen C. and Cregg J. M. 2002. Production of recombinant proteins in fermenter cultures of the yeast *Pichia pastoris*. *Curr Opin Biotechnol* **13**: 329 – 332.
- Chames P., Van Regenmortel M., Weiss E., Baty D. 2009. Therapeutic antibodies: successes, limitations and hopes for the future. *Br J Pharmacol.***157**(2):220-33.
- Chang H. J., Choi S. W., Chun H. S. 2008. Expression of functional single-chainvariable domain fragment antibody (scFv) against mycotoxinzearalenone in *Pichia pastoris*. *Biotechnol Lett***30**:1801-1806.
- Chester K. A., Begent R. H., Robson L., Keep P., Pedley R. B., Boden J. A., Boxer G., Green A., Winter G., Cochet O.1994 Phage libraries for generation of clinically useful antibodies. *Lancet***343**:455–456.
- Christoph M. Hammers and John R. Stanley 2014. Antibody Phage Display: Technique and Applications. *Journal of Investigative Dermatology***134**: e17.
- Clackson T., Hoogenboom H. R., Griffiths A. D., and Winter G. 1991. Making antibody fragments using phage display libraries. *Nature***352**:624–628.

- Clare J.J., Rayment F. B., Ballantine S. P., et al. High-level expression of tetanus toxin fragment C in *Pichia pastoris* strains containing multiple tandem integrations of the gene. *Bio-Technology***9**:455–460.
- Coleman J. W. 2002. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. *Clin. Exp. Immunol.***129**: 4–10.
- Cos O., Serrano A., Montesinos J. L., Ferrer P., Cregg J. M., Valero F. 2005. Combined effect of the methanol utilization (Mut) phenotype and gene dosage on recombinant protein production in *Pichia pastoris* fed-batch cultures. *J Biotechnol***116**:321–335.
- Couderc R. and Baratti J. 1980. Oxidation of methanol by the yeast *Pichia pastoris*: purification and properties of alcohol oxidase. *Agric. Biol. Chem.***44**: 2279–2289.
- Coughlin M., Lou G., Martinez O., Masterman S. K., Olsen O. A., Moksa A. A., Farzan M., Babcook J. S., Prabhakar B. S. 2007. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. *Virology***361**:93–102.
- Cregg J. M. 1999. Expression in methylotrophic yeast *Pichia pastoris*. In: Gene Expression systems, Fernander J. M., Hoeffler J. P., Eds., *Academic Press*, San Diego, 157–191.
- Cregg J. M. and Russell K. A. Transformation 1998. *Pichia* Protocols. *Humana*, Totowa, New Jersey: 27–39.
- Cregg J. M., Madden K. R. 1988. Development of the methylotrophic yeast, *Pichia pastoris*, as a host system for the production of foreign proteins. *Development in industrial microbiology***29**: 33–41.

- Cregg J. M., Madden K. R., Barringer K. J., Thill G., Stillman C. A. 1989. Functional characterization of the two alcohol oxidase genes from the yeast *Pichia pastoris*. *Mol Cell Biol*. **9**:1316–1323.
- Cregg J. M., Cereghino J.L, Shi J., Higgins D.R. 2000. Recombinant protein expression in *Pichia pastoris*. *Mol Biotechnol*. **16**(1):23-52.
- Cregg J.M, Madden K.R. 1987. Development of yeast transformation systems and construction of methanol-utilizationdefective mutants of *Pichia pastoris* by gene disruption. Biological research on Industrial Yeasts. *CRC Press, Boca Raton, FL* **2**: 1-18.
- Cregg J.M., Tschopp J.F., Stillman C., Siegel R., Akong M., Craig W.S., Buckholz R.G., Madden K.R., Kellaris P.A., Davis G.R., Smiley B.L., Cruze J., Torregrossa R., Velicelebi G., Thill G.P. 1987. High level expression and efficient assembly of hepatitis B surface antigen in the methylotrophic yeast, *Pichia pastoris*. *Bio-Technology* **5**: 479–485.
- Damasceno L. M., PlaI., ChangH. J., CohenL., RitterG., OldL. J. and BattC. A. 2004. An optimized fermentation process for high-level production of single-chain Fv antibody fragment in *Pichia pastoris*. *Protein Expr. Purif*. **37**: 18-26.
- Danese S., Colombel J.-F., Peyrin-Biroulet L., Rutgeerts P. & Reinisch W. 2013. Review article: the role of anti-TNF in the management of ulcerative colitis – past, present and future. *Aliment Pharmacol Ther*. **37**:855–866.
- Davidson A. and Diamond B. 2001. Autoimmune diseases. *N. Engl. J. Med*. **345**:340–350.
- Davies E. L., Smith J. S., Birkett C. R., Manser J. M., Anderson D. D. and Young J. R. 1995. Selection of specific phage-display antibodies using libraries derived from chicken immunoglobulin genes. *J. Immunol. Methods*. **186**:125–135.

- de Goffau M. C, Luopajarvi K., Knip M., Ilonen J., Ruotula T., Harkonen T., Orivuori L., Hakala S., Welling G. W., Harmsen H. J., Vaarala O. 2013. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. *Diabetes* **62**:1238–1244.
- de Haard H. J., van Neer N., Reurs A., Hufton S. E., Roovers R. C., Henderikx P., et al. 1999. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. *J. Biol. Chem.* **274**:18,218-230.
- De Schutter K., Lin Y-C., Tiels P., Van Hecke A., Glinka S., Weber-Lehmann J., Rouzé P., Van de Peer Y., Callewaert N. 2009. Genome sequence of the recombinant protein production host *Pichia pastoris*. *Nat Biotechnol.* **27**:561–566.
- de Wildt R. M., Mundy C. R., Gorick B. D., Tomlinson I. M. 2000. Antibody arrays for high-throughput screening of antibody-antigen interactions. *Nat Biotechnol.* **18**(9):989.
- Del Sal G., Manfioletti G. and Shneider, C. 1989. The CTAB-DNA precipitation method: a common mini-scale preparation of template DNA from phagemida, phagemids, phages or plasmid suitable for sequencing. *Biotechniques* **7**:514-520.
- Denzin L.K., Voss Jr. E.W. 1992. Construction, characterization, and mutagenesis of an anti-fluorescein single chain antibody idiotype family. *J. Biol. Chem.* **267**:8925–8931.
- Devauchelle V., Marion S., Cagnard N., Mistou S., Falgarone G., Breban M., Letourneur F., Pitaval A., Alibert O., Lucchesi C., Anract P., Hamadouche M., Ayral X., Dougados M., Gidrol X., Fournier C., Chiochia G. 2004. DNA

- microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. *Genes Immun.***5**:597–608.
- Dirk Ponsel, Julia Neugebauer, Kathrin Ladetzki-Baehs and Kathrin Tissot 2011. High Affinity, Developability and Functional Size: The Holy Grail of Combinatorial Antibody Library Generation. *Molecules***16**(5): 3675-3700.
- Doty J.D., Mazur J. E. and Judson M. A. 2005. Treatment of Sarcoidosis with Infliximab. *Chest***127**(3):1064-1071.
- Duilio A., Tutino M. L., Marino G. 2004. Recombinant protein production Antarctic gram negative bacteria. *Methods in Molecular Biology* **267**:225-238.
- Dunn C. J., Hardee M. M. and Staite N. D. 1989. Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and IFN-in mice. *Agents Actions***27**: 290-293.
- Eck M. J. and Sprang S. R. 1989. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. *J. Biol. Chem.* **264**:17595-17605.
- Eckart M. R. and Bussineau C. M. 1996. Quality and authenticity of heterologous proteins synthesized in yeast. *Current Opinion in Biotechnology***7**:525-530.
- Eldin P., Pauza M. E., Hieda Y., Lin G., Murtaugh M. P., Pentel P. R., Pennell C. A. 1997. High-level secretion of two antibody single chain Fv fragments by *Pichia pastoris*. *J Immunol Methods***201**:67-75.
- Ellis S. B., Brust P. F., Koutz P. J., Waters A. F., Harphold M. M., Gingeras T. R. 1985. Isolation of alcohol oxidase and two other methanol regulatable genes from the yeast *Pichia pastoris*. *Mol Cell Biol***5**:1111–1121.
- Faber K. N., Harder W., Ab G. and Veenhuis M. 1995. Review: Methylophilic yeasts as factories for the production of foreign proteins. *Yeast***11**:1331–1344.
- Farh K. K., Marson A., Zhu J., Kleinewietfeld M., Housley W. J., Beik S., Shores N., Whitton H., Ryan R. J., Shishkin A. A., Hatan M., Carrasco-Alfonso M. J.,

- Mayer D, Luckey C. J., Patsopoulos N. A., De Jager P. L., Kuchroo V. K., Epstein C. B., Daly M. J., Hafler D. A., Bernstein B. E. 2015. Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature***518**(7539):337-343.
- Feldmann M., Brennan F. M. and Maini R. N. 1995. Human Cytokines: Their Role in Disease and Therapy: Role of cytokines in autoimmune diseases. Blackwell Science, Boston **185**-194.
- Feldmann M., Maini R. N. 2001. Anti-TNF α therapy of rheumatoid arthritis: What have we learned? *Annu. Rev. Immunol.***19**:163–96.
- Fischer R., Drossard J., Emans N., Commandeur U., Hellwig S. 1999. Towards molecular farming in the future: *Pichia pastoris*-based production of single-chain antibody fragments. *Biotechnol Appl Biochem***30**:117–120.
- Fleischmann R., J. Vencovsky, R. F. van Vollenhoven, D. Borenstein, J. Box, G. Coteur, N. Goel, H-P. Brezinschek, A. Innes, .V Strand 2009. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis***68**:805-811.
- Freund C., Gehrig P., Holak T. A. & PluÈ ckthun A. 1997. Comparison of the amide proton exchange behavior of the rapidly formed folding intermediate and the native state of an antibody scFv fragment. *FEBS Letters***407**:42-46.
- Freyre F.M., Vazquez J.E., Ayala M., Canaan-Haden L., Bell H., Rodriguez I., Gonzalez A., Cintado A., Gavilondo J.V. 2000 Very high expression of an anti-carcinoembryonic antigen single chain Fv antibody fragment in the yeast *Pichia pastoris*. *J Biotechnol***76**:157–163.
- Giraud E., Primo L., Audero E., Gerber H. P., Koolwijk P., Soker S., Klagsbrun M., Ferrara N. and Bussolino F. 1998. Tumor necrosis factor-alpha regulates

- expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. *J. Biol. Chem.***273**: 22128-22135.
- Gonçalves A. C., Marson F. A., Mendonça R. M., Ribeiro J. D., Ribeiro A. F., Paschoal I. A., et al. 2013. Saliva as a potential tool for cystic fibrosis diagnosis. *Diagn Pathol***8**:46.
- Good R.A. & Lorenz E. 1991. Historic aspects of intravenous immunoglobulin therapy. *Cancer***68**:1415–1421.
- Graff C. P., Chester K., Begent R., Wittrup K. D. 2004. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. *Protein Eng Des Sel***7**(4):293-304.
- Graham A. L., Allen J. E. and Read A. F. 2005. Evolutionary causes and consequences of immunopathology. *Annu. Rev. Ecol. Evol. Syst.***36**:373–93.
- Gram H., Marconi L., Barbas C. F., Collet T. A., Lerner R. A. and Kang A. S. 1992. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. *Proc. Natl. Acad. Sci. USA* **89**: 3576–3580.
- Greenough T. C., Babcock G. J., Roberts A., Hernandez H. J., Thomas W. D. Jr, Coccia J. A., Graziano R. F., Srinivasan M., Lowy I., Finberg R. W., Subbarao K., Vogel L., Somasundaran M., Luzuriaga K., Sullivan J. L., Ambrosino D. M. 2005. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. *J. Infect. Dis.* **191**: 507–514.
- Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. 1995. The

- transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell***83**: 793–802
- Griffiths A. D., Malmqvist M., Marks J. D., Bye J. M., Embleton M. J., McCafferty J., Baier M., Holliger K. P., Gorick B. D., Hughes-Jones 1993. Human anti-self-antibodies with high specificity from phage display libraries. *Embo J.* **12**:725–734.
- Griffiths A.D., Williams S. C., Hartley O., Tomlinson I. M., Waterhouse P., Crosby W. L., Kontermann R. E., Jones P. T., Low N. M., Allison T. J. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. *EMBO J.* **13**, 3245–3260.
- Hans R. Waterham, Kimberly A. Russell, Yne de Vries and James M. Cregg 1997. Peroxisomal Targeting, Import, and Assembly of Alcohol Oxidase in *Pichia pastoris*. *J. Cellular Biology***139**(6):1419-1431
- Hansson M., Nygren P. A. and Stahl S. 2000. Design and production of recombinant subunit vaccines. *Biotechnology and Applied Biochemistry* **32**:95-107.
- Harris L. J., Larson S. B., Hasel K. W., Day J., Greenwood A. and McPherson A. 1992. The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. *Nature***360**:369-372.
- Harris L. J., Skaletsky E. and McPherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. *J. Mol. Biol.* **275**: 861-872.
- Hetland M. L., Christensen I. J., Tarp U., Dreyer L., Hansen A., Hansen I. T., Kollerup G. et al. 2010. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. *Arthritis Rheum.***62**(1):22-32.

- Hewitt L. & McDonnell J.M. 2004. Screening and optimizing protein production in *E. coli*. *Meth. Mol. Biol.* **278**:1–16.
- Hoet R.M. et al. 2005. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. *Nat. Biotechnol.* **23**:344–348.
- Hoffman C. S. and Winston F. 1987. A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of *Escherichia coli*. *Gene* **57**:267–272.
- Hohenblum H., Gasser B., Maurer M., Borth, N. and Mattanovich D. 2004. Effects of gene dosage, promoters, and substrates on unfolded protein stress of recombinant *Pichia pastoris*. *Biotechnol Bioeng* **85**:367–375.
- Holt L.J., Bussow K., Walter G. and Tomlinson I. M. 2000. By-passing selection: direct screening for antibody-antigen interactions using protein arrays. *Nucleic Acids Res.* **28**: e72.
- Hoogenboom H. R. 2002. Overview of antibody phage-display technology and its applications. *Methods Mol Biol.* **178**:1–37.
- Hoogenboom H. R. 2005. Selecting and screening recombinant antibody libraries. *Nat. Biotechnol.* **23**:1105–1116.
- Hoogenboom H. R. and Chames P. 2000. Natural and designer binding sites made by phage display technology. *Immunol. Today* **21**:371–378.
- Hoogenboom H.R. and Winter G. 1992. By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. *J. Mol. Biol.* **227**: 381–388.
- Hsu H., Huang J., Shu H. B., Baichwal V., Goeddel D.V. 1996. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. *Immunity* **4**(4):387–96.

- Huse W.D., Sastry L., Iverson S. A., Kang A. S., Alting-Mees M., Burton D. R., Benkovic S. J., Lerner R. A. 1989. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. *Science* **246**:1275–1281.
- Hust M. and Dubel S. 2004. Mating antibody phage display with proteomics. *Trends Biotechnol.* **22**: 8–14.
- Iwalewa E. O., McGaw L. J., Naidoo V. and Eloff J. N. 2007. Inflammation: the foundation of diseases and disorders. A review of phytomedicines of South African origin used to treat pain and inflammatory conditions. *African Journal of Biotechnology* **6**(25): 2868–2885.
- JafariRozbeh, Birgitta E. Sundström and Patrik Holm 2011. Optimization of production of the anti-keratin8 single-chain Fv TS1-218 in *Pichia pastoris* using design of experiments. *Microbial Cell Factories* **10**:34.
- Jones E. Y., Stuart D. I. and Walker N. P. 1989. Structure of tumour necrosis factor. *Nature* **338**: 225–228.
- Jones P. T., Dear P. H., Foote J., Neuberger M. S. and Winter G. 1986 Replacing the complementarity-determining regions in a human antibody with those of a mouse. *Nature* **321**: 522–525.
- Joosten V., Lokman C., Van Den Hondel C. A., Punt P. J. 2003. The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. *Microb Cell Fact.* **2**:1.
- Jose U. Scher, carlesubeda, Alejandro Artacho, mukundanattur, Sandrine Isaac, Soumya M. Reddy, Shoshana Marmon, Andrea Neimann, Samuel Brusca, Tejas Patel, Julia Manasson, Eric G. Pamer, Dan R. Littman and Steven B. Abramson. 2015. Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease. *Arthritis & rheumatology* **67**(1): 128–139.

- Kavanaugh A., McInnes I., Mease P., Krueger G.G., Gladman D., Gomez-Reino J., Papp K., Zrubek J., Mudivarthi S., Mack M., Visvanathan S., Beutler A. 2009. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum.***60**:976–986.
- Kaymakcalan Z., Sakorafas P., Bose S., Scesney S., Xiong L., Hanzatian D. K., Salfeld J., Sasso E. H. 2009. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. *Clin Immunol.* 2009 **131**(2):308-16.
- Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica L., Schwieterman W.D., Siegel J.N., Braun M.M. 2001. Tuberculosis associated with Infliximab, a tumor necrosis factor-alpha neutralizing agent. *N. Engl. J. Med.***345**:1098–1104.
- Kettleborough C. A., Ansell K. H., Allen R. W., Rosell-Vives E., Gussow D. H., and Bendig M. M. 1994. Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments. *Eur. J. Immunol.* **24**:952–958.
- Khatri Narendar K. and Hoffmann Frank 2006. Oxygen-limited control of methanol uptake for improved production of a single-chain antibody fragment with recombinant *Pichia pastoris*. *Appl Microbiol Biotechnol***72**:492–498.
- Kindt T. J., Goldsby R.A., Osbourne B.A. 2007. Kuby immunology. Sixth ed. W.H.
- Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhöfer G., Hoess A., Wölle J., Plückthun A., Virnekäs B. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. *J. Mol. Biol.***296**: 57–86.

- Kohler G. and Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* **256**:495-497.
- Koichi Ogata, Hideo Nishikawa and Masahiro Ohsugi 1969. A Yeast Capable of Utilizing Methanol. *Agricultural and Biological Chemistry* **33**(10):1519-1520.
- Kollias G., Douni E., Kassiotis G. and Kontoyiannis D. 1999a. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. *Annu. Rheum. Dis.* **58**:132-139.
- Kollias G., Douni E., Kassiotis G., Kontoyiannis D., 1999b. On the role of tumor necrosis factor and receptors in models of multi organ failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. *Immunol. Rev.* **169**:175-194.
- Koutz P, Davis G. R., Stillman C., Barringer K., Cregg J., Thill G. 1989. Structural comparison of the *Pichia pastoris* alcohol oxidase genes. *Yeast* **5**(3):167-77.
- Krebber A., Bornhauser S., Burmester J., Honegger A., Willuda J., Bosshard H. R., Plückthun A. 1997. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. *J Immunol Methods* **201**(1):35-55.
- Küberl A., Schneider J., Thallinger G. G., Anderl I., Wibberg D., Hajek T., Jaenicke S., Brinkrolf K., Goesmann A., Szczepanowski R., Pühler A., Schwab H., Glieder A., Pichler H. 2011. High-quality genome sequence of *Pichia pastoris* CBS7435. *J Biotechnol.* **154**:312-320.
- Kwasnikowski P., Kristensen P. and Markiewicz W.T. 2005. Multivalent display system on filamentous bacteriophage pVII minor coat protein. *J. Immunol. Methods* **307**:135-143.

- Lang I. M., Barbas C. F. and Schleef R. R. 1996. Recombinant rabbit Fab with binding activity to type-1 plasminogen activator inhibitor derived from a phage-display library against human alpha-granules. *Gene* **172**: 295–298.
- Lawren C. Wu 2015. Preparing for a career in biopharma research. *Trends in immunology* **36**(5):290-292.
- Lee C. M., Iorno N., Sierro F. et al. 2007 Selection of human antibody fragments by phage display. *Nat Protoc* **2**:3001–8.
- Lefranc M. P. 2001. IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res* **29**(1):207-209.
- Li T., ChengJ., HuB., LiuY., QuianG. and Liu F. 2008. Construction, production, and characterization of recombinant scFv antibodies against methamidophos expressed in *Pichia pastoris*. *World J. Microbiol. Biotechnol* **24**: 867-874.
- Liljequist S. and Stahl S. 1999. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. *Journal of Biotechnology* **73**:1-33.
- Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis, anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. *N. Engl. J. Med.* **343**:1594–1602.
- Liu H., Tan X., Russell K. A., Veenhuis M., Cregg J. M. 1995. PER3, a gene required for peroxisome biogenesis in *Pichia pastoris*, encodes a peroxisomal membrane protein involved in protein import. *J Biol Chem* **270**(18): 10 940.
- Lu C. F., Montijn R. C., Brown J. L., et al. 1995. Glycosyl phosphatidylinositol-dependent cross-linking of α -agglutinin and β 1, 6-glucan in the *Saccharomyces cerevisiae* cell wall. *J Cell Biol.* **128**:333–340.

- Lu Deng, Ming Luo, Alejandro Velikovskyy and Roy A. Mariuzza 2013. Structural Insights into the Evolution of the Adaptive Immune System. *Annu. Rev. Biophys.***42**:191–215.
- Macauley-Patrick S., L. M. Fazenda B. McNeil and L. M. Harvey. 2005. Heterologous protein production using the *Pichia pastoris* expression system. *Yeast* **22**: 249–270.
- Maher J., Vintiner S., Elliot D. and Melia L. 2002. Evaluation of the BioSign PSA membrane test for the identification of semen stains in forensic casework. *N. Z. Med. J.***115**: 48–49.
- Mallender W.D., Carrero J., Voss Jr. E.W. 1996. Comparative properties of the single chain antibody and Fv derivatives of mAb 4-4-20. *J. Biol. Chem.***271**:5338–534.
- Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D. and Winter G. 1991. By-passing immunization: Human antibodies from V-gene libraries displayed on phage. *J. Mol. Biol.***222**: 581–597.
- Marrack P., Kappler J. and Kotzin B. L. 2001. Autoimmune disease: why and where it occurs. *Nature Med.***7**:899–905.
- May M.J. and Ghosh S. 1998. Signal transduction through NF-kappa B. *Immunology today***19**:80–88.
- McCafferty J., and Johnson K. S. 1996. Construction and screening of antibody display libraries. In: BK KayJ. WinterJ. McCafferty. Phage display of peptides and proteins. San Diego, California: *Academic Press, Inc.* 79–111.
- McCafferty J., Griffiths A. D., Winter G. and Chiswell D. J. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. *Nature***348**(6301) 552–554.
- McKinney J., Knappskog P. M., Pereira J., Ekern T., Toska K., Kuitert B. B., Levine D., Gronenborn A., Martínez A., Haavik J. 2004. Expression and Purification of

- Human Tryptophan Hydroxylase from *Escherichia coli* and *Pichia pastoris*. *Prot. Exp. Purif.***33**:185-194.
- Mease P. J. 2011. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. *Rheumatology (Oxford)***50**(2): 261–270.
- Merck, Sharp, Dohne Ltd. Simponi, summary of product characteristic. 2011.
- Moore R. J., Owens D. M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B, Pasparakis M., et al.1999. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. *Nat Med.* **5**:828–831.
- Morgan M.J., Liu Z. G. 2010. Reactive oxygen species in TNFalpha-induced signaling and cell death *Mol Cells***30**(1):1-12.
- Mullinax R L., Gross E. A., Amberg J. R., Hay B. N., Hogleve H. H., Kubitz M.M., Greener A., Alting M.M., Ardouel D. and Short J. M. 1990. Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunoexpression library. *Proc. Natl. Acad. Sci. USA* **87**: 6450-6454.
- Nett J. H., Hodel N., Rausch S., Wildt S. 2005. Cloning and disruption of the *Pichia pastoris* ARG1, ARG2, ARG3, HIS1, HIS2, HIS5, HIS6 genes and their use as auxotrophic markers. *Yeast***22**:295–304.
- Neuberger M. and Brüggenmann M. 1997. Mice perform a human repertoire. *Nature* **386**:25–26.
- Nissim A., Hoogenboom H. R., Tomlinson I. M., Flynn G., Midgley C., Lane D. and Winter G. 1994. Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. *EMBO J.***13**: 692–698.
- Nylund L., Satokari R., Nikkila J., Rajilic-Stojanovic M., Kalliomaki M., Isolauri E., Salminen S., de Vos W. M. 2013. Microarray analysis reveals marked intestinal

- microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. *BMC Microbiol.***13**:12.
- Ogunijimi A., Chandler J., Gooding C., Recinos A. and Choudary P. 1999. High-level secretory expression of immunologically active intact antibody from yeast *Pichia pastoris*. *Biotechnol. Lett.***21**: 561-567.
- Old L. 1985. Tumor necrosis factor (TNF). *Science***230**: 630-632.
- Orlandi O., Gussow D. H., Jones P.T. and Winter G. 1989. Cloning immunoglobulin variable domains for the expression by the polymerase chain reaction. *Proc. Natl. Acad. Sci. USA* **86**: 3833-3837.
- Orosz P., Echtenacher B., Falk W., Ruschoff J., Weber D. and Mannel D. N. 1993. Enhancement of experimental metastasis by tumor necrosis factor. *J. Exp. Med.***177**: 1391-1398.
- Ossysek K., Uchański T., Kulesza M., Bzowska M., Klaus T., Woś K., Madej M., Bereta J. A new expression vector facilitating production and functional analysis of scFv antibody fragments selected from Tomlinson I+J phagemid libraries. *Immunol Lett.***167**(2):95-102.
- Owens T., Wekerle H. and Antel J. 2001. Genetic models for CNS inflammation. *Nature Med.***7**:161-166.
- Palframan R., Airey M., Moore A., Vugler A., Nesbitt A. 2009. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. *J Immunol Methods***348**(1-2):36-41.
- Palladino M.A., Bahjat F.R., Theodorakis E.A., Moldawer L.L. 2003. Anti-TNF-therapies: the next generation. *Nat. Rev. Drug Discov.* **2**:736-746.
- Pancer Z., Cooper M. 2006. The evolution of adaptive immunity. *Annu. Rev. Immunol.***24**:497-518.

- Papadakis K.A. 2009. Crohn's disease: Adalimumab improves quality of life. *Nat Rev Gastroenterol Hepatol*. **6**(4):200-201.
- Paramsivam M., Saravanan K., Uma K., *et al.* 2002. Expression, purification and characterization of equine lactoferrin in *Pichia pastoris*. *Prot. Exp. Pur.* **26**: 28–34.
- Persson M. A. A., Caothien R. H. and Burton D. R. 1991. Generation of diverse high affinity human monoclonal antibodies by repertoire cloning. *Proc. Natl. Acad. Sci. USA* **88**: 2432-2436.
- Pini A., Bracci L. 2000. Phage display of antibody fragments. *Curr Protein Pept Sci.* **1**(2):155-69.
- Pliickthun A. 1991. Antibody engineering: advances from the use of *Escherichia coli* expression systems. *BioTechnology***9**: 545-551.
- Pliickthun A. and Skerra A. 1989. Expression of of functional Fv and Fab fragments In *E. coli*. *Meth. Enzymol.***178**: 497-515.
- Ploss M., Kuhn A. 2010. Kinetics of filamentous phage assembly. *Phys Biol.* **9**; **7**(4):045002.
- Potgieter T. I., M. Cukan, J. E. Drummond, N. R. Houston-Cummings, Y. Jiang, F. Li, *et al.* 2009. Production of monoclonal antibodies by glycoengineered *Pichia pastoris*. *J. Biotechnol.***139**: 318-325.
- Probert L., Akassoglou K, Pasparakis M., Kontogeorgos G., Kollias G. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. *Proc. Natl. Acad. Sci. USA* **92**:11294–11298.
- Queen C., Schneider W. P., Slick H. E., Payne P. W., Landolfi N. F., Duncan J. F., Avdalovic N. M., Levitt M., Junghans R. P. and Waldmann T. A. 1989. A

- humanized antibody that binds to the interleukin 2 receptor. *Proc. Natl. Acad. Sci. USA* **86**: 10029-10033.
- Raberg L., Grahm M., Hasselquist D., Svensson E. 1998. On the adaptive significance of stress-induced immunosuppression. *Proc. R. Soc. Lond. B* **265**:1637–41
- Raemaekers R. J., de Muro L., Gatehouse J. A., Fordham-Skelton A. P. 1999. Functional phytohemagglutinin (PHA) and *Galanthus nivalis* agglutinin (GNA) expressed in *Pichia pastoris* correct N-terminal processing and secretion of heterologous proteins expressed using the PHA-E signal peptide. *Eur J Biochem.* **265**:394–403.
- Raffai R., Vukmirica J., Weisgraber K. H., Rassart E., Innerarity T. L., Milne R. 1999. Bacterial expression and purification of the Fab fragment of a monoclonal antibody specific for the low-density lipoprotein receptor-binding site of human apolipoprotein E. *Protein Expr. Purif.* **16**:84–90.
- Rampart M., De Smet W., Fiers W. and Herman A. G. 1989. Inflammatory properties of recombinant tumor necrosis factor in rabbit skin in vivo. *J. Exp. Med.* **169**:2227-2232.
- Richard A. Goldsby, Thomas J. Kindt, Barbara A. Osborne and Janis Kuby 2000. Kuby Immunology 4th edition, W H Freeman & Co.
- Romanos M. A., Scorer C. A., Clare J. J. 1992. Foreign gene expression in yeast: a review. *Yeast* **8**:423-488.
- Roovers R. C., van der Linden E., Zijlema H., de Bruijne A., Arends J. W., Hoogenboom H. R. 2001. Evidence for a bias toward intracellular antigens in the local humoral anti-tumor immune response of a colorectal cancer patient revealed by phage display. *Int. J. Cancer* **93**: 832–840.
- Sandborn W. J., Hanauer S. B., Katz S., Safdi M., Wolf D. G., Baerg R. D., Tremaine W. J., Johnson T., Diehl N. N., Zinsmeister A. R. 2001. Etanercept for Active

- Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. *Gastroenterology* **121**(5):1088-1094.
- Saphire E. O., Parren P. W., Pantophlet R., Zwick M. B., Morris G. M., Rudd P. M., Dwek R. A., Stanfield R. L., Burton D. R. and Wilson I. A. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. *Science* **293**:1155- 1159.
- Sheehan K. C., Pinckard J. K., Arthur C. D., Dehner L. P., Goeddel D. V., Schreiber R. D. 1995. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. *J. Exp. Med.* **181**(2):607-17.
- Shen S., Sulter G., Jeffries T. W., Cregg J. M. 1998. A strong nitrogen source-regulated promoter for controlled expression of foreigngenes in the yeast *Pichia pastoris*. *Gene* **216**: 93–102.
- Shi X., Karkut T., Chamankhah M., Alting-Mees M., Hemmingsen S. M.,Hegedus D. 2003. Optimal conditions for the expression of a single-chainantibody (scFv) gene in *Pichia pastoris*. *Protein Expr Puri* **28**:321-330.
- Sidhu, S. S., Li B., Chen Y., Fellouse F. A., Eigenbrot C., Fuh G. 2004. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. *J. Mol. Biol.* **338**: 299–310.
- Silacci, M, Brack S., Schirru G., Mårilind J., Ettorre A., Merlo A., Viti F., Neri D. 2005. Design, construction, and characterization of a large synthetic human antibody phage display library. *Proteomics* **5**:2340–2350.
- Skerra A. and Pluckthun A. 1988. Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*. *Science* **240**:1038–1041.

- Slibinskas R., Samuel D., Gedvilaite A., Staniulis J. & Sasnauskas K. 2004. Synthesis of the measles virus nucleoprotein in yeast *Pichia pastoris* and *Saccharomyces cerevisiae*. *J Biotechnol* **107**: 115–124.
- Sloan, S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., Rowley K. J., Mandell R. B., Babcock G. J., Thomas W. D. Jr, Rupprecht C. E., Ambrosino D. M. 2007. Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. *Vaccine* **25**:2800–2810.
- Smith D. A., Germolec D. R. 1999. Introduction to Immunology and Autoimmunity. *Environmental Health Perspectives* **107**(5): 661–665.
- Smith G. P., Petrenko V. A. 1997. Phage Display. *Chem Rev.* 1; **97**(2):391–410.
- Smith G.P. 1985. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science* **228**: 1315–1317.
- Söderlind E., Strandberg L., Jirholt P., Kobayashi N., Alexeiva V., Aberg A.M., Nilsson A., Jansson B., Ohlin M., Wingren C., Danielsson L., Carlsson R., Borrebaeck C. A. 2000. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. *Nat. Biotechnol.* **18**: 852–856.
- Sophie Candon, Alicia Perez-Arroyo, Cindy Marquet, Fabrice Valette, Anne-Perrine Foray, Benjamin Pelletier, Cristian Milani , Marco Ventura, Jean-François Bach, Lucienne Chatenoud. 2015. Antibiotics in Early Life Alter the Gut Microbiome and Increase Disease Incidence in a Spontaneous Mouse Model of Autoimmune Insulin-Dependent Diabetes. *PLoS One* **10**(5): e0125448.
- Storb U., Shen H.M., Michael N. and Kim N. 2001. Somatic hypermutation of immunoglobulin and non-immunoglobulin genes. *Philos. Trans. R. Soc. Lond. B. Biol. Sci.* **356**:13–19.

- Susumu Tonegawa 1983. Somatic generation of antibody diversity. *Nature***302**(14): 575-581.
- Tan P. H., Sandmaier B. M. & Stayton P. S. 1998. Contribution of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. *Biophys. J.***75**:1473-1482.
- Taylor P. C. 2010. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. *Current Opinion in pharmacology***10**(3):308-315.
- Tiwari A., A. Sankhyani, N. Khanna, S. Sinha 2010. Enhanced periplasmic expression of high affinity humanized scFv against Hepatitis B surface antigen by codon optimization. *Protein Expr. Purif.***74**: 272-279.
- Tomlinson I. M. Walter G., Marks J. D. Llewelyn M. B. and Winter G. 1992. The repertoire of human germline V_H segments reveals fifty groups of V_H segments with different hypervariable loops. *J. Mol. Biol.***227**: 776-798.
- Tracey K. J. and Cerami A. 1994. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. *Annu. Rev. Med.***45**:491-503.
- Tschopp J. F., Brust P. F., Cregg J. M., Stillman C. A., Gingeras T. R. 1987. Expression of the lacZ gene from two methanol-regulated promoters in *Pichia pastoris*. *Nucleic Acids Res***15**:3859- 3876.
- Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., et al., 2009. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry. *Arthritis & Rheumatism* **60**(7):1884-1894.
- Twan van den Beucken, Henk Pieters, Mieke Steukers, Marcel van der Vaart, Robert Charles Ladner, Hennie R Hoogenboom, Simon E Hufton 2003. Affinity

- maturation of Fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries. *FEBS Lett.***546**(2-3):288-94.
- UCB Pharma Ltd. Chimzia, summary of product characteristic. 2011.
- Utz J. P., Limper A. H., Kalra S., Specks U., Scott J. P., Vuk-Pavlovic Z., Schroeder D. R. 2003. Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis. *Chest***124**(1):177-185.
- Van Ostade X., Vandenabeele P., Tavernier J. and Fiers W. 1994. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. *Eur. J. Biochem.***220**:771-779.
- Vaughan T. J., Williams A. J., Pritchard K., Osbourn J. K., Pope A. R., Earnshaw J. C., McCafferty J, Hodits R. A., Wilton J., Johnson K. S. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. *Nature Biotechnol.***14**:309–314.
- Veenhuis M., and Harder W. 1987. Metabolic significance and biogenesis of microbodies in yeast. In: Peroxisomes in Biology and Medicine, ed. D. Fahimi, H. Sies, Berlin: *Springer-Verlag*, 436-457.
- Veenhuis M., van Dijken J.P. and Harder W. 1983. The significance of peroxisomes in the metabolism of one-carbon compounds in yeast. *Adv. Microb. Physiol.***24**:1-82.
- Verhoeyen M., Milstein C. and Winter G. 1988. Reshaping human antibodies: grafting an anti-lysozyme activity. *Science***239**: 1534-1536.
- Virginia Pascual, Damien Chaussabel and Jacques Banchereau 2010. A Genomic Approach to Human Autoimmune Diseases. *Annu. Rev. Immunol.***28**:535–71
- Vyse T. J. & Todd J. A. 1996. Genetic analysis of autoimmune disease. *Cell***85**, 311–318.

- Wallach D., Engelmann H., Nophar Y., Aderka D., Kemper O., Hornik V., Holtmann H., Brakebusch C. 1991. Soluble and cell surface receptors for tumor necrosis factor. *Agents Actions Suppl.***35**: 51–57.
- Ward E.S., Gussow D.H., Griffiths A., Jones P.T. and Winter G. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*. *Nature***341**: 544–546.
- Wayne A. Marasco and Jianhua Sui. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. *Nature Biotechnology***25**:12.
- Werten M. W. T., van den Bosch T. J., Wind R. D., Mooibroek H., de Wolf F. A. 1999. High-yield secretion of recombinant gelatins by *Pichia pastoris*. *Yeast***15**:1087–1096.
- Wheyth pharmaceuticals. Enbrel, summary of product characteristic. 2011.
- Winter G. and Milstein C. 1991. Man-made antibodies. *Nature* **349**:293–299.
- Winter G., Griffiths A. D., Hawkins R. E., Hoogenboom H. R. 1994. Making antibodies by phage display technology. *Annu Rev Immunol.* **12**:433–55.
- Wu T. T., Kabat E. A. 1970. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. *J. Exp. Med.* **132**(2):211–50.
- Yamanaka H. I., Inoue T. and Ikeda T. O. 1996. Chicken monoclonal antibody isolated by a phage display system. *J. Immunol.* **157**:1156–1162.
- Yang G., Zhou H., Lu Y., Lin Y., Zhou S. 2004a. Comparing expression of different forms of human DNA topoisomerase I in *Pichiapastoris*. *Enz Microb Techno***34**(2): 139–146.
- Ye J., J. Ly, K. Watts, A. Hsu, A. Walker, K. McLaughlin, et al. 2011. Optimization of a glycoengineered *Pichia pastoris* cultivation process for commercial antibody production. *Biotechnol. Prog.***27**: 1744–1750.

- Zaccolo M. and Gherardi E. 1999. The effect of high-frequency random mutagenesis on in vitro protein evolution: a study on TEM-1 beta-lactamase. *J. Mol. Biol.***285**: 775–783.
- ZuhaidaAsra Ahmad, SweeKeongYeap, Abdul Manaf Ali, Wan Yong Ho, NoorjahanBanu Mohamed Alitheen and Muhajir Hamid. 2012. scFv Antibody: Principles and Clinical Application. *Clinical and Developmental Immunology***2012**:980250.